Clinical Outcomes of Trimethoprim/Sulfamethoxazole in Critically Ill Patients with Stenotrophomonas maltophilia Bacteremia and Pneumonia Utilizing Renal Replacement Therapies

Wasim S. El Nekidy, Khaled Al Zaman, Emna Abidi, Diaa Alrahmany, Islam M. Ghazi, Rania M. El-Lababidi, Mohamad Mooty, Fadi Hijazi, Muriel Ghosn, Mohamed Askalany, Mohamed Helal, Ahmed Taha, Khaled M. Ismail, Jihad MallatJournal of Clinical Medicine 2024 · DOI

TL;DR

This study investigated the effectiveness of Trimethoprim/Sulfamethoxazole (TMP/SMZ) in critically ill patients with Stenotrophomonas maltophilia infections who were on renal replacement therapy (RRT). The findings indicate that standard TMP/SMZ dosing in this vulnerable patient population leads to high rates of treatment failure and mortality, suggesting a need for revised dosing strategies or alternative treatments.

What Problem Does This Paper Address?

Stenotrophomonas maltophilia (S. maltophilia) is a multidrug-resistant bacterium that poses a significant threat, particularly to critically ill patients, often causing severe infections like pneumonia and bacteremia. For patients with kidney failure requiring renal replacement therapy (RRT), managing such infections is complex because their altered kidney function affects how drugs are processed and eliminated. Trimethoprim/Sulfamethoxazole (TMP/SMZ) is a common antibiotic choice for S. maltophilia, but its optimal dosing in critically ill patients on RRT (including hemodialysis and continuous renal replacement therapy) has not been well-established. This lack of clarity creates a challenge for clinicians aiming to provide effective treatment while minimizing adverse effects in these highly vulnerable patients.

Methods

This was a retrospective observational study conducted at a single institution. The researchers reviewed the medical records of critically ill adult patients who had S. maltophilia infections and were receiving RRT between May 2015 and January 2022. They collected data on patient demographics, clinical characteristics, microbiological findings, and TMP/SMZ treatment details. The primary outcome measured was clinical cure, with secondary outcomes including microbiologic cure, infection recurrence, and mortality. Statistical analyses, including multivariable logistic regression, were used to identify factors associated with clinical success.

Datasets

Not discussed in the paper. The study utilized retrospective patient data collected from a single institution.

Key Insights and Ideas

  • RRT significantly complicates antibiotic dosing: The core challenge is that RRT modalities (like hemodialysis and continuous renal replacement therapy) can significantly alter the clearance of antibiotics, making standard dosing protocols potentially ineffective or toxic.
  • Standard TMP/SMZ dosing is insufficient for critically ill RRT patients: Despite S. maltophilia isolates being susceptible to TMP/SMZ in laboratory tests, the real-world outcomes in this specific patient group were poor. This highlights a critical disconnect between in vitro susceptibility and clinical efficacy.
  • Higher doses might be better, but with caution: The study found that patients who achieved clinical success tended to receive higher median daily doses of TMP/SMZ, particularly those on continuous veno-venous hemofiltration. This suggests that higher doses might be necessary, but the risk of adverse events needs careful consideration.
  • Mortality is a major concern: The significantly higher mortality rate in the clinical failure group underscores the severity of S. maltophilia infections in this population and the potential inadequacy of current treatment strategies.

Key Results

  • High Failure Rate: 60% of patients experienced clinical failure with TMP/SMZ treatment.
  • Significant Mortality: 90-day mortality was high at 48.9%, with no deaths in the clinical success group but a substantial proportion (81.5%) in the clinical failure group.
  • Dose Matters: The total daily dose of TMP/SMZ at the start of therapy was identified as the only independent factor associated with clinical success, even after adjusting for other variables.
  • Adverse Events: Common adverse events included thrombocytopenia (55.5%) and hyperkalemia (42%), with hyperkalemia being significantly more prevalent in the clinical failure group.
  • CVVH vs. IHD Dosing: Patients on continuous veno-venous hemofiltration (CVVH) in the clinical success group received a higher median daily dose (1064 mg) compared to the clinical failure group (768 mg), a difference that was statistically significant. For intermittent hemodialysis (IHD), the trend was reversed, with the clinical success group receiving a lower median dose (500 mg) compared to the clinical failure group (640 mg), though this difference was not statistically significant.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: As with all retrospective studies, there's a potential for selection bias and reliance on documented data, which may not capture all nuances.
  • Single-Center Study: The findings are from one institution, limiting generalizability.
  • Small Sample Size: With only 45 patients, the statistical power to detect smaller differences might be limited.
  • Concomitant Antibiotics: The study did not exclude patients receiving other antibiotics, which could have influenced outcomes and made it difficult to isolate the effect of TMP/SMZ.
  • Lack of Drug Level Monitoring: Therapeutic drug monitoring (measuring actual drug levels in the blood) was not performed, which is crucial for optimizing dosing in RRT patients.
  • Colonization vs. Infection: Distinguishing between true infection and colonization with S. maltophilia can be challenging, although elevated inflammatory markers in this study suggested infection.

The authors strongly recommend larger, prospective studies focusing on pharmacokinetics and clinical outcomes to establish optimal TMP/SMZ dosing strategies for critically ill patients on RRT. They also suggest the need for therapeutic drug monitoring to personalize treatment.

Summary updated

Abstract

<b>Background</b>: The clinical outcomes of usual doses of Trimethoprim-sulfamethoxazole (TMP/SMZ) for treating <i>S. maltophilia</i> in critically ill patients on renal replacement therapies (RRT) have not been established. We sought to assess the clinical outcomes of TMP/SMZ in patients with sepsis utilizing RRT. <b>Methods</b>: A retrospective study was performed on all critically ill adult patients with <i>S. maltophilia</i> infections who received RRT between May 2015 and January 2022. The primary endpoint was clinical cure while the secondary endpoints were microbiologic cure, 30-day infection recurrence, and mortality. <b>Results</b>: Forty-five subjects met the inclusion criteria. The median age was 70.0 [interquartile range (IQR): 63.5-77] years, 57.8% were males, and the median body mass index was 25.7 [IQR: 22-30.2] kg/m<sup>2</sup>. Clinical success and failure were reported in 18 (40%) and 27 (60%) cases, respectively. There was no significant difference between the 30-day reinfection rates of both groups; however, mortality was significantly higher in the clinical failure group, involving 12 patients (44.4%), versus none in the clinical success group (<i>p</i> = 0.001). The median daily dose of TMP/SMZ upon continuous veno-venous hemofiltration was 1064 [IQR: 776-1380] mg in the clinical cure group vs. 768 [IQR:540-1200] mg in the clinical failure group (<i>p</i> = 0.035). Meanwhile, the median dose for those who received intermittent hemodialysis was 500 [IQR: 320-928] mg in the clinical success group compared to 640 [IQR: 360-1005] mg in the clinical failure group (<i>p</i> = 0.372). A total of 55% experienced thrombocytopenia, 42% hyperkalemia, and 2.2% neutropenia. The multivariable logistic regression analysis showed that the total daily dose at therapy initiation was the only independent factor associated with clinical success after adjusting for different variables including the body mass index [Odds ratio 1.004; 95% confidence interval: (1-1.007), <i>p</i> = 0.044]. <b>Conclusions</b>: Although the <i>S. maltophilia</i> isolates were reported as susceptible, TMP/SMZ with conventional doses to treat bacteremia and pneumonia in critically ill patients utilizing RRT was associated with high rates of clinical and microbiologic failure as well as with mortality. Larger outcomes and pharmacokinetics studies are needed to confirm our findings.
BibTeX
@article{nekidy2024clinical,
  author = {Wasim S. El Nekidy and Khaled Al Zaman and Emna Abidi and Diaa Alrahmany and Islam M. Ghazi and Rania M. El-Lababidi and Mohamad Mooty and Fadi Hijazi and Muriel Ghosn and Mohamed Askalany and Mohamed Helal and Ahmed Taha and Khaled M. Ismail and Jihad Mallat},
  title = {{Clinical Outcomes of Trimethoprim/Sulfamethoxazole in Critically Ill Patients with Stenotrophomonas maltophilia Bacteremia and Pneumonia Utilizing Renal Replacement Therapies}},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  doi = {10.3390/jcm13082275},
}
Figure